Effects of Oligo-fucoidan on Leiomyoma Patients
Effects of Oligo-fucoidan on Leiomyoma Patients
NCT ID: NCT06959966 Phase: EARLY_PHASE1 Status: COMPLETED Enrollment: 18 Completion: 2023-01-31
Conditions
Uterine Leiomyoma
Interventions
Placebo, Oligo Fucoidan
Summary
Uterine leiomyoma is the most common benign tumor in women, with an incidence rate of approximately 20% among women of reproductive age. Patients may experience severe abdominal pain, abnormal bleeding, and infertility. Pathological examination of uterine specimens reveals that up to three-quarters of cases involve uterine leiomyoma, indicating that this condition is often accompanied by other uterine pathologies. Therefore, medical intervention remains necessary for affected patients. Currently, the most common treatment options include medication and surgical removal. However, the severe side effects of drug therapy and the high recurrence rate following surgical excision significantly impact patients' quality of life, underscoring the need for continued research into better treatment strategies. Fucoidan, a commercially available dietary supplement, has been shown in numerous studies to provide adjunctive therapeutic benefits for cancer patients. However, no clinical trials have been conducted to evaluate the effects of fucoidan on patients with uterine leiomyoma. Therefore, this clinical study aims to investigate the effects of fucoidan on patients with uterine leiomyoma.
Primary Outcome
Change in Leiomyoma Size